Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

November 6, 2021

1 Mins read

November 6, 2021

1 Mins read

FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #DecisionDxMelanoma–Castle announced the publication of a study validating performance of the i31-SLNB algorithm to determine sentinel lymph node biopsy positivity risk.

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

Stay Updated

Content Partner

Related posts

Accenture and Splunk Form Business Group to Help Organizations Capitalize on Cloud and Drive Greater Value From Data and Analytics Insights

Automated Sales & Underwriting Strategies can Transform Insurance

Top 4 AI engines to look out for in 2022

Wipro Partners With National Grid to Drive Data Center Consolidation and Implement Next Generation Hybrid Cloud Architecture

Top 7 Steps CXOs Should Take To Overcome

DIGITAL TRANSFORMATION